{"title":"组织功能受损对抗骨质疏松药物药代动力学的影响","authors":"Tatsuo Takahashi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>It is necessary to achieve pharmacotherapy appropriate to individual patient with respect to effectiveness and safety. Since drugs are given to patients with various kinds of diseases and conditions, in which pharmacokinetics greatly changes, we need to understand the relationship between pharmacokinetics and patient's condition, minimizing the individual differences in drug efficacy and toxicity. In this report, I outline the alteration of pharmacokinetics of anti-osteoporotic drugs in patients with various diseases and conditions.</p>","PeriodicalId":502100,"journal":{"name":"Clinical calcium","volume":"26 11","pages":"1539-1545"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Effect of impaired tissue function on pharmacokinetics of anti-osteoporotic drugs.]\",\"authors\":\"Tatsuo Takahashi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It is necessary to achieve pharmacotherapy appropriate to individual patient with respect to effectiveness and safety. Since drugs are given to patients with various kinds of diseases and conditions, in which pharmacokinetics greatly changes, we need to understand the relationship between pharmacokinetics and patient's condition, minimizing the individual differences in drug efficacy and toxicity. In this report, I outline the alteration of pharmacokinetics of anti-osteoporotic drugs in patients with various diseases and conditions.</p>\",\"PeriodicalId\":502100,\"journal\":{\"name\":\"Clinical calcium\",\"volume\":\"26 11\",\"pages\":\"1539-1545\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical calcium\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Effect of impaired tissue function on pharmacokinetics of anti-osteoporotic drugs.]
It is necessary to achieve pharmacotherapy appropriate to individual patient with respect to effectiveness and safety. Since drugs are given to patients with various kinds of diseases and conditions, in which pharmacokinetics greatly changes, we need to understand the relationship between pharmacokinetics and patient's condition, minimizing the individual differences in drug efficacy and toxicity. In this report, I outline the alteration of pharmacokinetics of anti-osteoporotic drugs in patients with various diseases and conditions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
